Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada
IMPACT Project Protocol: Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada
1 other identifier
observational
400
1 country
13
Brief Summary
Active metropolitan area surveillance for hospital admissions related to invasive infection with Neisseria meningitidis will be conducted at the 12 centers in the IMPACT network in collaboration with Public Health officials, local infection specialists and infection control practitioners during the interval from January 1, 2016 to December 31, 2022.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2016
Longer than P75 for all trials
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedFirst Submitted
Initial submission to the registry
November 28, 2019
CompletedFirst Posted
Study publicly available on registry
December 3, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedApril 11, 2022
April 1, 2022
7 years
November 28, 2019
April 4, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Laboratory confirmed invasive meningococcal cases.
Laboratory confirmed invasive meningococcal cases.
End of 2021
Study Arms (1)
Persons of all ages
Persons of all ages admitted between January 1, 2016 and December 31, 2022 with a positive result of Neisseria meningitidis isolated or detected by PCR from a normal sterile site, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy
Interventions
Eligibility Criteria
Any person admitted with confirmation of an invasive meningococcal infection at all participating Centers across Canada
You may not qualify if:
- clinical signs, gram stain, or antigen test
- meningococci isolated only from respiratory tract, including conjunctiva, sinuses, middle ear/mastoid, throat, peritonsillar abscess, cervical lymph node, tracheal aspirate, bronchial lavage etc -
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Canadian Paediatric Societylead
- Pfizercollaborator
- GlaxoSmithKlinecollaborator
Study Sites (13)
Alberta Children's Hospital
Calgary, Alberta, T3B 6A8, Canada
Stollery Children's Hospital
Edmonton, Alberta, T6G 1C9, Canada
BC Children's Hospital
Vancouver, British Colombia, V5Z 4H4, Canada
Children's Hospital Research Institute of Manitoba
Winnipeg, Manitoba, R3E 3P4, Canada
Eastern Health Janeway Children's and Rehabilitation Centre
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
IWK Health Centre
Halifax, Nova Scotia, B3K6R8, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, K1H 8L1, Canada
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
CHU- Sainte Justine
Montreal, Quebec, H3T 1C5, Canada
Montreal Children's Hospital
Montreal, Quebec, H4A 3J1, Canada
Centre Mere-Enfant Soleil CHU de Quebec
Québec, Quebec, G1V 4G2, Canada
Royal University Hospital
Saskatoon, Saskatchewan, S7N 0W8, Canada
McMaster's Children Hospital
Hamilton, L8S4K1, Canada
Related Links
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 28, 2019
First Posted
December 3, 2019
Study Start
January 1, 2016
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
April 11, 2022
Record last verified: 2022-04
Data Sharing
- IPD Sharing
- Will not share